KR101940341B1 - 약학 조성물 - Google Patents

약학 조성물 Download PDF

Info

Publication number
KR101940341B1
KR101940341B1 KR1020137029608A KR20137029608A KR101940341B1 KR 101940341 B1 KR101940341 B1 KR 101940341B1 KR 1020137029608 A KR1020137029608 A KR 1020137029608A KR 20137029608 A KR20137029608 A KR 20137029608A KR 101940341 B1 KR101940341 B1 KR 101940341B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
oxytocin
buffer
cys
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137029608A
Other languages
English (en)
Korean (ko)
Other versions
KR20140019830A (ko
Inventor
커스틴 우브나스-모버그
앤더스 칼손
Original Assignee
펩-토닉 메디칼 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 펩-토닉 메디칼 에이비 filed Critical 펩-토닉 메디칼 에이비
Publication of KR20140019830A publication Critical patent/KR20140019830A/ko
Application granted granted Critical
Publication of KR101940341B1 publication Critical patent/KR101940341B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020137029608A 2011-04-14 2012-04-13 약학 조성물 Expired - Fee Related KR101940341B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161475471P 2011-04-14 2011-04-14
SE1150324A SE536091C2 (sv) 2011-04-14 2011-04-14 Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
US61/475,471 2011-04-14
SE1150324-0 2011-04-14
PCT/EP2012/056813 WO2012140216A1 (en) 2011-04-14 2012-04-13 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
KR20140019830A KR20140019830A (ko) 2014-02-17
KR101940341B1 true KR101940341B1 (ko) 2019-01-18

Family

ID=47008851

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137029608A Expired - Fee Related KR101940341B1 (ko) 2011-04-14 2012-04-13 약학 조성물

Country Status (17)

Country Link
US (1) US9034821B2 (enExample)
EP (1) EP2696882B1 (enExample)
JP (1) JP5993442B2 (enExample)
KR (1) KR101940341B1 (enExample)
CN (1) CN103596582B (enExample)
AU (1) AU2012241805B2 (enExample)
BR (1) BR112013026153A2 (enExample)
CA (1) CA2832664C (enExample)
DK (1) DK2696882T3 (enExample)
ES (1) ES2535521T3 (enExample)
IL (1) IL228821A (enExample)
PL (1) PL2696882T3 (enExample)
RU (1) RU2605288C2 (enExample)
SE (1) SE536091C2 (enExample)
SG (1) SG194074A1 (enExample)
WO (1) WO2012140216A1 (enExample)
ZA (1) ZA201308157B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014057092A1 (en) * 2012-10-12 2014-04-17 Pep-Tonic Medical Ab Novel use of a composition comprising oxytocin
SG11201705591PA (en) 2015-01-07 2017-08-30 Trigemina Inc Magnesium-containing oxytocin formulations and methods of use
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) * 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
PT3369429T (pt) * 2015-10-30 2020-02-20 Teijin Pharma Ltd Composição farmacêutica para administração na mucosa nasal
HRP20250215T1 (hr) 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
SE1750680A1 (en) * 2017-05-30 2018-12-01 Peptonic Medical Ab Composition for treating or preventing climacteric disorders
CN114288253B (zh) * 2018-09-20 2024-04-02 阿卡蒂亚药品公司 稳定的鼻内卡贝缩宫素制剂
CN110169377B (zh) * 2019-06-27 2021-09-14 浙江海洋大学 黄姑鱼的人工催产受精方法
SE547797C2 (en) 2023-09-25 2025-11-25 Letavis Ab Stimulation of plant germination

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042452A1 (en) 2006-09-29 2008-04-10 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions comprising oxytocin or an analog for the treatment of autism
WO2010118888A1 (en) 2009-04-17 2010-10-21 Merz Pharma Gmbh & Co. Kgaa Formulation for stabilizing proteins, which is free of mammalian excipients

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076797A (en) 1957-07-22 1963-02-05 Roussel Uclaf Process of producing oxytocin and intermediates obtained thereby
US2938991A (en) 1957-10-01 1960-05-31 Candace Inc Electric mattress pad
JPS61126014A (ja) * 1984-11-22 1986-06-13 Teijin Ltd 経鼻投与用水性液剤
SE466134B (sv) 1990-11-22 1992-01-07 Kabi Pharmacia Ab Gelbildande flytande baerarkomposition samt anvaendning daerav i farmaceutiska kompositioner
JP3179538B2 (ja) * 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト 安定なヒトカルシトニンの水性溶液
GB9326354D0 (en) 1993-12-23 1994-02-23 British Aerospace Methods and apparatus for the testing,monitoring and improvement of manufacturing process effectiveness
SE9400918L (sv) * 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
US5833647A (en) * 1995-10-10 1998-11-10 The Penn State Research Foundation Hydrogels or lipogels with enhanced mass transfer for transdermal drug delivery
ATE247456T1 (de) 1996-02-27 2003-09-15 Teijin Ltd Puderförmige zusammensetzung zur nasalen anwendung
SE9701162D0 (sv) 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
SE9701161D0 (sv) 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
SE9701184D0 (sv) 1997-04-01 1997-04-01 Karolinska Innovations Ab Substanser för att åstadkomma preferens och skapa acceptans
SE9803272D0 (sv) 1998-09-25 1998-09-25 Kerstin Uvnaes Moberg A drug for cell regeneration
SE0001440D0 (sv) * 2000-04-18 2000-04-18 Entretech Medical Ab A drug against climacteric disorders
SE0100684D0 (sv) * 2001-02-28 2001-02-28 Kerstin Uvnaes Moberg New subject-matter
SE0102184D0 (sv) 2001-06-19 2001-06-19 Uvnaes Moberg Kerstin New subject-matter
SE0102910D0 (sv) * 2001-08-31 2001-08-31 Moberg Kerstin Uvnaes New use
JO2492B1 (en) * 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
US7884076B2 (en) * 2003-11-06 2011-02-08 The Trustees Of Columbia University In The City Of New York Multipeptide regimen for the treatment of autistic spectrum, behavioral, emotional and visceral inflammation/autoimmune disorders
AU2005267396B2 (en) * 2004-06-24 2009-09-17 Idexx Laboratories, Inc. Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042452A1 (en) 2006-09-29 2008-04-10 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions comprising oxytocin or an analog for the treatment of autism
WO2010118888A1 (en) 2009-04-17 2010-10-21 Merz Pharma Gmbh & Co. Kgaa Formulation for stabilizing proteins, which is free of mammalian excipients

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Endocrinology. Vol. 63, No. 5, pp. 679-687 (1958)

Also Published As

Publication number Publication date
RU2013147739A (ru) 2015-05-20
US20140171369A1 (en) 2014-06-19
ZA201308157B (en) 2015-01-28
AU2012241805A1 (en) 2013-10-24
CN103596582B (zh) 2016-03-16
JP5993442B2 (ja) 2016-09-14
DK2696882T3 (en) 2015-04-27
SE536091E5 (enExample) 2015-04-21
IL228821A (en) 2016-08-31
IL228821A0 (en) 2013-12-31
EP2696882A1 (en) 2014-02-19
CN103596582A (zh) 2014-02-19
JP2014515747A (ja) 2014-07-03
EP2696882B1 (en) 2015-03-04
RU2605288C2 (ru) 2016-12-20
PL2696882T3 (pl) 2015-08-31
US9034821B2 (en) 2015-05-19
BR112013026153A2 (pt) 2019-09-17
SE1150324A1 (sv) 2012-10-15
AU2012241805B2 (en) 2016-08-11
CA2832664C (en) 2020-03-24
CA2832664A1 (en) 2012-10-18
ES2535521T3 (es) 2015-05-12
HK1189158A1 (en) 2014-05-30
WO2012140216A1 (en) 2012-10-18
SE536091C2 (sv) 2013-04-30
SG194074A1 (en) 2013-11-29
KR20140019830A (ko) 2014-02-17

Similar Documents

Publication Publication Date Title
KR101940341B1 (ko) 약학 조성물
CH683749A5 (de) Pharmazeutische Nasalzusammensetzung.
BRPI0616300A2 (pt) formulaÇço aquosa de hfsh
JP6800372B2 (ja) 持続型パルミチン酸結合ＧｎＲＨ誘導体及びこれを含む薬剤学的組成物
CN106924721B (zh) 经口腔黏膜给药的含人甲状旁腺激素的药物组合物
JP6629877B2 (ja) 鼻粘膜投与用医薬組成物
EP2908840A1 (en) Novel use of a composition comprising oxytocin
JP2004527496A (ja) 新規物質
JP2021130688A (ja) 女性対象における不妊症の治療ための組成物
TW201440783A (zh) 含有米卡芬淨或其鹽的醫藥組成物
NZ242440A (en) Fibrillated calcitonin and its preparation
NZ223533A (en) A dried protein product coated with an ionic surfactant whereby protein bioactivity and solubility is maintained and method of preparation
CN114096269A (zh) 高浓度胰岛素制剂
TWI322692B (en) Fsh and lh pharmaceutical formulations
HK40004511A (en) Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid
KR20170083064A (ko) 치료 동종이량체 및 그의 용도

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240115

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240115